RNDO-564-001: A first-in-human, phase 1/1b study of RNDO-564, a bispecific antibody for the treatment of advanced bladder cancer and other tumors associated with Nectin-4 expression. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results